These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9750517)

  • 1. [Recent advance in luteinizing hormone-releasing hormone analogue therapy in management of prostate cancer].
    Kawai K; Akaza H
    Nihon Rinsho; 1998 Aug; 56(8):2108-13. PubMed ID: 9750517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB; Campion M
    Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
    Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
    Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
    Weckermann D; Harzmann R
    Eur Urol; 2004 Sep; 46(3):279-83; discussion 283-4. PubMed ID: 15306097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
    Engel JB; Schally AV
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.
    Akaza H
    Pharmacology; 2010; 85(2):110-20. PubMed ID: 20130444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical or medical castration with LH-RH analogue for prostatic cancer].
    Kameyama S; Yamazaki S; Kitamura T
    Nihon Rinsho; 1998 Aug; 56(8):2114-8. PubMed ID: 9750518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for prostate cancer: the role of hormonal treatment.
    Shahani R; Fleshner NE; Zlotta AR
    Discov Med; 2007 Aug; 7(39):118-24. PubMed ID: 18093474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of LHRH antagonists in the treatment of prostate cancer.
    Crawford ED; Hou AH
    Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
    Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
    Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer.
    Blumberg JM; Kwon EO; Cheetham TC; Niu F; Shapiro CE; Pacificar J; Loo RK; Williams SG; Chien GW
    Urology; 2011 Feb; 77(2):412-6. PubMed ID: 21111460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment].
    Ueda S; Nishi K; Yoshida M
    Nihon Rinsho; 1998 Aug; 56(8):2119-23. PubMed ID: 9750519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
    Koga H; Naito S
    Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.